Akademik Veri Yönetim Sistemi
Turkish Journal of Dermatology, cilt.15, sa.3, ss.66-73, 2021 (Hakemli Dergi)
Background: Chronic urticaria (CU) is defined as the persistence of urticarial lesions for more than 6 weeks. Omalizumab, a human
monoclonal anti IgE antibody, has been used as a new therapeutic option in CU patients unresponsive to high-dose second-generation
antihistamines. Aims and Objectives: This study is aimed to examine the clinical and demographic characteristics of CU patients treated
with omalizumab in our clinic and to define parameters related to therapeutic response. Materials and Methods: Patients who were
followed up with the diagnosis of CU between January 2014 and June 2020 were evaluated retrospectively. The data obtained from
patients’ electronic files were analyzed using SPSS23 program. Results: 167 patients (125 female, 42 male) were included. The mean
age was 45.34 ± 14.76 years. The mean disease duration at the onset of omalizumab was found to be 47.41 ± 63.26 months. Complete
response to treatment was observed in 45.9%, 48%, and 52% of patients at 3rd, 6th, and 12th months of omalizumab treatment,
respectively. The baseline total IgE level was evaluated in 107 patients and a statistically significant correlation was observed between
complete response to treatment at 3rd month and higher baseline total IgE levels (P < 0.001). Conclusion: Omalizumab provided a
significant therapeutic response and the patients did not need any other treatment, while patients with high pretreatment IgE levels
showed a better and earlier response. These results may guide clinicians in predicting patients’ response to omalizumab.